Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 84 entries
Sorted by: Best Match Show Resources per page
Molecular autopsy and subsequent functional analysis reveal de novo DSG2 mutation as cause of sudden death.

European journal of medical genetics

Simons E, Labro A, Saenen J, Nijak A, Sieliwonczyk E, Vandendriessche B, Dąbrowska M, Van Craenenbroeck EM, Schepers D, Van Laer L, Loeys BL, Alaerts M.
PMID: 34438094
Eur J Med Genet. 2021 Nov;64(11):104322. doi: 10.1016/j.ejmg.2021.104322. Epub 2021 Aug 23.

Sudden cardiac death (SCD) is a common cause of death in young adults. In up to 80% of cases a genetic cause is suspected. Next-generation sequencing of candidate genes can reveal the cause of SCD, provide prognostic management, and...

Cite
Simons E, Labro A, Saenen J, et al. Molecular autopsy and subsequent functional analysis reveal de novo DSG2 mutation as cause of sudden death. Eur J Med Genet. 2021;64(11):104322doi: 10.1016/j.ejmg.2021.104322.
Simons, E., Labro, A., Saenen, J., Nijak, A., Sieliwonczyk, E., Vandendriessche, B., Dąbrowska, M., Van Craenenbroeck, E. M., Schepers, D., Van Laer, L., Loeys, B. L., & Alaerts, M. (2021). Molecular autopsy and subsequent functional analysis reveal de novo DSG2 mutation as cause of sudden death. European journal of medical genetics, 64(11), 104322. https://doi.org/10.1016/j.ejmg.2021.104322
Simons, Eline, et al. "Molecular autopsy and subsequent functional analysis reveal de novo DSG2 mutation as cause of sudden death." European journal of medical genetics vol. 64,11 (2021): 104322. doi: https://doi.org/10.1016/j.ejmg.2021.104322
Simons E, Labro A, Saenen J, Nijak A, Sieliwonczyk E, Vandendriessche B, Dąbrowska M, Van Craenenbroeck EM, Schepers D, Van Laer L, Loeys BL, Alaerts M. Molecular autopsy and subsequent functional analysis reveal de novo DSG2 mutation as cause of sudden death. Eur J Med Genet. 2021 Nov;64(11):104322. doi: 10.1016/j.ejmg.2021.104322. Epub 2021 Aug 23. PMID: 34438094.
Copy Download .nbib Format: NLM
Pik3c3 deficiency in myeloid cells imparts partial resistance to experimental autoimmune encephalomyelitis associated with reduced IL-1β production.

Cellular & molecular immunology

Yang G, Song W, Xu J, Postoak JL, Cheng F, Martinez J, Zhang J, Wu L, Van Kaer L.
PMID: 33235386
Cell Mol Immunol. 2021 Aug;18(8):2024-2039. doi: 10.1038/s41423-020-00589-1. Epub 2020 Nov 24.

The PIK3C3/VPS34 subunit of the class III phosphatidylinositol 3-kinase (PtdIns3K) complex plays a role in both canonical and noncanonical autophagy, key processes that control immune-cell responsiveness to a variety of stimuli. Our previous studies found that PIK3C3 is a...

Cite
Yang G, Song W, Xu J, et al. Pik3c3 deficiency in myeloid cells imparts partial resistance to experimental autoimmune encephalomyelitis associated with reduced IL-1β production. Cell Mol Immunol. 2020;18(8):2024-2039doi: 10.1038/s41423-020-00589-1.
Yang, G., Song, W., Xu, J., Postoak, J. L., Cheng, F., Martinez, J., Zhang, J., Wu, L., & Van Kaer, L. (2021). Pik3c3 deficiency in myeloid cells imparts partial resistance to experimental autoimmune encephalomyelitis associated with reduced IL-1β production. Cellular & molecular immunology, 18(8), 2024-2039. https://doi.org/10.1038/s41423-020-00589-1
Yang, Guan, et al. "Pik3c3 deficiency in myeloid cells imparts partial resistance to experimental autoimmune encephalomyelitis associated with reduced IL-1β production." Cellular & molecular immunology vol. 18,8 (2021): 2024-2039. doi: https://doi.org/10.1038/s41423-020-00589-1
Yang G, Song W, Xu J, Postoak JL, Cheng F, Martinez J, Zhang J, Wu L, Van Kaer L. Pik3c3 deficiency in myeloid cells imparts partial resistance to experimental autoimmune encephalomyelitis associated with reduced IL-1β production. Cell Mol Immunol. 2021 Aug;18(8):2024-2039. doi: 10.1038/s41423-020-00589-1. Epub 2020 Nov 24. PMID: 33235386; PMCID: PMC8322046.
Copy Download .nbib Format: NLM
The influence of COVID-19 on routine hematological parameters of hospitalized patients.

Acta clinica Belgica

Blomme S, Smets L, Van Ranst M, Boeckx N, Van Laer C.
PMID: 32886893
Acta Clin Belg. 2020 Sep 04;1-6. doi: 10.1080/17843286.2020.1814649. Epub 2020 Sep 04.

OBJECTIVES: Coronavirus disease 2019 (COVID-19) was first discovered in Wuhan, China, in December 2019, and soon spread around the entire world. As no effective treatment is known, prediction of disease severity is very important in order to estimate a...

Cite
Blomme S, Smets L, Van Ranst M, et al. The influence of COVID-19 on routine hematological parameters of hospitalized patients. Acta Clin Belg. 2020;1-6doi: 10.1080/17843286.2020.1814649.
Blomme, S., Smets, L., Van Ranst, M., Boeckx, N., & Van Laer, C. (2020). The influence of COVID-19 on routine hematological parameters of hospitalized patients. Acta clinica Belgica, 1-6. https://doi.org/10.1080/17843286.2020.1814649
Blomme, S, et al. "The influence of COVID-19 on routine hematological parameters of hospitalized patients." Acta clinica Belgica vol. (2020): 1-6. doi: https://doi.org/10.1080/17843286.2020.1814649
Blomme S, Smets L, Van Ranst M, Boeckx N, Van Laer C. The influence of COVID-19 on routine hematological parameters of hospitalized patients. Acta Clin Belg. 2020 Sep 04;1-6. doi: 10.1080/17843286.2020.1814649. Epub 2020 Sep 04. PMID: 32886893.
Copy Download .nbib Format: NLM
Dendritic cell PIK3C3/VPS34 controls the pathogenicity of CNS autoimmunity independently of LC3-associated phagocytosis.

Autophagy

Yang G, Postoak JL, Song W, Martinez J, Zhang J, Wu L, Van Kaer L.
PMID: 33960279
Autophagy. 2021 May 07;1-10. doi: 10.1080/15548627.2021.1922051. Epub 2021 May 07.

PIK3C3/VPS34 is a key player in macroautophagy/autophagy and MAP1LC3/LC3-associated phagocytosis (LAP), which play critical roles in dendritic cell (DC) function. In this study, we assessed the contribution of PIK3C3 to DC function during experimental autoimmune encephalomyelitis (EAE), an animal...

Cite
Yang G, Postoak JL, Song W, et al. Dendritic cell PIK3C3/VPS34 controls the pathogenicity of CNS autoimmunity independently of LC3-associated phagocytosis. Autophagy. 2021;1-10doi: 10.1080/15548627.2021.1922051.
Yang, G., Postoak, J. L., Song, W., Martinez, J., Zhang, J., Wu, L., & Van Kaer, L. (2021). Dendritic cell PIK3C3/VPS34 controls the pathogenicity of CNS autoimmunity independently of LC3-associated phagocytosis. Autophagy, 1-10. https://doi.org/10.1080/15548627.2021.1922051
Yang, Guan, et al. "Dendritic cell PIK3C3/VPS34 controls the pathogenicity of CNS autoimmunity independently of LC3-associated phagocytosis." Autophagy vol. (2021): 1-10. doi: https://doi.org/10.1080/15548627.2021.1922051
Yang G, Postoak JL, Song W, Martinez J, Zhang J, Wu L, Van Kaer L. Dendritic cell PIK3C3/VPS34 controls the pathogenicity of CNS autoimmunity independently of LC3-associated phagocytosis. Autophagy. 2021 May 07;1-10. doi: 10.1080/15548627.2021.1922051. Epub 2021 May 07. PMID: 33960279.
Copy Download .nbib Format: NLM
Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation.

Scientific reports

Hasenfratz M, Mellert K, Marienfeld R, von Baer A, Schultheiss M, Roitman PD, Aponte-Tinao LA, Lehner B, Möller P, Mechtersheimer G, Barth TFE.
PMID: 33707617
Sci Rep. 2021 Mar 11;11(1):5709. doi: 10.1038/s41598-021-85319-x.

Giant cell tumor of bone (GCTB) is a locally aggressive lesion of intermediate malignancy. Malignant transformation of GCTB is a rare event. In 2013, the humanized monoclonal antibody against receptor activator of nuclear factor-κb-Ligand (RANKL) denosumab was approved for...

Cite
Hasenfratz M, Mellert K, Marienfeld R, et al. Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation. Sci Rep. 2021;11(1):5709doi: 10.1038/s41598-021-85319-x.
Hasenfratz, M., Mellert, K., Marienfeld, R., von Baer, A., Schultheiss, M., Roitman, P. D., Aponte-Tinao, L. A., Lehner, B., Möller, P., Mechtersheimer, G., & Barth, T. F. E. (2021). Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation. Scientific reports, 11(1), 5709. https://doi.org/10.1038/s41598-021-85319-x
Hasenfratz, Marc, et al. "Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation." Scientific reports vol. 11,1 (2021): 5709. doi: https://doi.org/10.1038/s41598-021-85319-x
Hasenfratz M, Mellert K, Marienfeld R, von Baer A, Schultheiss M, Roitman PD, Aponte-Tinao LA, Lehner B, Möller P, Mechtersheimer G, Barth TFE. Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation. Sci Rep. 2021 Mar 11;11(1):5709. doi: 10.1038/s41598-021-85319-x. PMID: 33707617; PMCID: PMC7952552.
Copy Download .nbib Format: NLM
Characterization of Immune Responses to SARS-CoV-2 and Other Human Pathogenic Coronaviruses Using a Multiplex Bead-Based Immunoassay.

Vaccines

Borena W, Kimpel J, Gierer M, Rössler A, Riepler L, Oehler S, von Laer D, Miholits M.
PMID: 34200301
Vaccines (Basel). 2021 Jun 07;9(6). doi: 10.3390/vaccines9060611.

Serological assays that simultaneously detect antibodies to multiple targets of SARS-CoV-2 and to other structurally related coronaviruses provide a holistic picture of antibody response patterns. Well-validated multiplex immunoassays are scarce. Here, we evaluated the performance of an 11-plex serological...

Cite
Borena W, Kimpel J, Gierer M, et al. Characterization of Immune Responses to SARS-CoV-2 and Other Human Pathogenic Coronaviruses Using a Multiplex Bead-Based Immunoassay. Vaccines (Basel). 2021;9(6)doi: 10.3390/vaccines9060611.
Borena, W., Kimpel, J., Gierer, M., Rössler, A., Riepler, L., Oehler, S., von Laer, D., & Miholits, M. (2021). Characterization of Immune Responses to SARS-CoV-2 and Other Human Pathogenic Coronaviruses Using a Multiplex Bead-Based Immunoassay. Vaccines, 9(6), . https://doi.org/10.3390/vaccines9060611
Borena, Wegene, et al. "Characterization of Immune Responses to SARS-CoV-2 and Other Human Pathogenic Coronaviruses Using a Multiplex Bead-Based Immunoassay." Vaccines vol. 9,6 (2021). doi: https://doi.org/10.3390/vaccines9060611
Borena W, Kimpel J, Gierer M, Rössler A, Riepler L, Oehler S, von Laer D, Miholits M. Characterization of Immune Responses to SARS-CoV-2 and Other Human Pathogenic Coronaviruses Using a Multiplex Bead-Based Immunoassay. Vaccines (Basel). 2021 Jun 07;9(6). doi: 10.3390/vaccines9060611. PMID: 34200301; PMCID: PMC8229387.
Copy Download .nbib Format: NLM
Cardiogeneticsbank@UZA: A Collection of DNA, Tissues, and Cell Lines as a Translational Tool.

Frontiers in medicine

Alaerts M, van de Beek G, Luyckx I, Meester J, Schepers D, Verstraeten A, Saenen J, Van Craenenbroeck E, Goovaerts I, Rodrigus I, Laga S, Hendriks J, Goethals S, De Wilde A, Smits E, Jorens P, Huizing M, Van Laer L, Loeys B.
PMID: 31555651
Front Med (Lausanne). 2019 Sep 06;6:198. doi: 10.3389/fmed.2019.00198. eCollection 2019.

Cardiogeneticsbank@UZA is an academic hospital integrated biobank that collects aortic tissue, blood, cell lines (fibroblasts, vascular smooth muscle cells, peripheral blood mononuclear cells, and induced pluripotent stem cells), and DNA from patients with cardiogenetic disorders, for both diagnostic and...

Cite
Alaerts M, van de Beek G, Luyckx I, et al. Cardiogeneticsbank@UZA: A Collection of DNA, Tissues, and Cell Lines as a Translational Tool. Front Med (Lausanne). 2019;6:198doi: 10.3389/fmed.2019.00198.
Alaerts, M., van de Beek, G., Luyckx, I., Meester, J., Schepers, D., Verstraeten, A., Saenen, J., Van Craenenbroeck, E., Goovaerts, I., Rodrigus, I., Laga, S., Hendriks, J., Goethals, S., De Wilde, A., Smits, E., Jorens, P., Huizing, M., Van Laer, L., & Loeys, B. (2019). Cardiogeneticsbank@UZA: A Collection of DNA, Tissues, and Cell Lines as a Translational Tool. Frontiers in medicine, 6198. https://doi.org/10.3389/fmed.2019.00198
Alaerts, Maaike, et al. "Cardiogeneticsbank@UZA: A Collection of DNA, Tissues, and Cell Lines as a Translational Tool." Frontiers in medicine vol. 6 (2019): 198. doi: https://doi.org/10.3389/fmed.2019.00198
Alaerts M, van de Beek G, Luyckx I, Meester J, Schepers D, Verstraeten A, Saenen J, Van Craenenbroeck E, Goovaerts I, Rodrigus I, Laga S, Hendriks J, Goethals S, De Wilde A, Smits E, Jorens P, Huizing M, Van Laer L, Loeys B. Cardiogeneticsbank@UZA: A Collection of DNA, Tissues, and Cell Lines as a Translational Tool. Front Med (Lausanne). 2019 Sep 06;6:198. doi: 10.3389/fmed.2019.00198. eCollection 2019. PMID: 31555651; PMCID: PMC6742711.
Copy Download .nbib Format: NLM
The Role of HPV and Non-HPV Sexually Transmitted Infections in Patients with Oropharyngeal Carcinoma: A Case Control Study.

Cancers

Kofler B, Laimer J, Bruckmoser E, Steinbichler TB, Runge A, Schartinger VH, von Laer D, Borena W.
PMID: 32397254
Cancers (Basel). 2020 May 08;12(5). doi: 10.3390/cancers12051192.

No abstract available.

Cite
Kofler B, Laimer J, Bruckmoser E, et al. The Role of HPV and Non-HPV Sexually Transmitted Infections in Patients with Oropharyngeal Carcinoma: A Case Control Study. Cancers (Basel). 2020;12(5)doi: 10.3390/cancers12051192.
Kofler, B., Laimer, J., Bruckmoser, E., Steinbichler, T. B., Runge, A., Schartinger, V. H., von Laer, D., & Borena, W. (2020). The Role of HPV and Non-HPV Sexually Transmitted Infections in Patients with Oropharyngeal Carcinoma: A Case Control Study. Cancers, 12(5), . https://doi.org/10.3390/cancers12051192
Kofler, Barbara, et al. "The Role of HPV and Non-HPV Sexually Transmitted Infections in Patients with Oropharyngeal Carcinoma: A Case Control Study." Cancers vol. 12,5 (2020). doi: https://doi.org/10.3390/cancers12051192
Kofler B, Laimer J, Bruckmoser E, Steinbichler TB, Runge A, Schartinger VH, von Laer D, Borena W. The Role of HPV and Non-HPV Sexually Transmitted Infections in Patients with Oropharyngeal Carcinoma: A Case Control Study. Cancers (Basel). 2020 May 08;12(5). doi: 10.3390/cancers12051192. PMID: 32397254; PMCID: PMC7281731.
Copy Download .nbib Format: NLM
Nanoparticle-Formulated Curcumin Prevents Posttherapeutic Disease Reactivation and Reinfection with .

Frontiers in immunology

Tousif S, Singh DK, Mukherjee S, Ahmad S, Arya R, Nanda R, Ranganathan A, Bhattacharyya M, Van Kaer L, Kar SK, Das G.
PMID: 28713372
Front Immunol. 2017 Jun 30;8:739. doi: 10.3389/fimmu.2017.00739. eCollection 2017.

Curcumin, the bioactive component of turmeric also known as "Indian Yellow Gold," exhibits therapeutic efficacy against several chronic inflammatory and infectious diseases. Even though considered as a wonder drug pertaining to a myriad of reported benefits, the translational potential...

Cite
Tousif S, Singh DK, Mukherjee S, et al. Nanoparticle-Formulated Curcumin Prevents Posttherapeutic Disease Reactivation and Reinfection with . Front Immunol. 2017;8:739doi: 10.3389/fimmu.2017.00739.
Tousif, S., Singh, D. K., Mukherjee, S., Ahmad, S., Arya, R., Nanda, R., Ranganathan, A., Bhattacharyya, M., Van Kaer, L., Kar, S. K., & Das, G. (2017). Nanoparticle-Formulated Curcumin Prevents Posttherapeutic Disease Reactivation and Reinfection with . Frontiers in immunology, 8739. https://doi.org/10.3389/fimmu.2017.00739
Tousif, Sultan, et al. "Nanoparticle-Formulated Curcumin Prevents Posttherapeutic Disease Reactivation and Reinfection with ." Frontiers in immunology vol. 8 (2017): 739. doi: https://doi.org/10.3389/fimmu.2017.00739
Tousif S, Singh DK, Mukherjee S, Ahmad S, Arya R, Nanda R, Ranganathan A, Bhattacharyya M, Van Kaer L, Kar SK, Das G. Nanoparticle-Formulated Curcumin Prevents Posttherapeutic Disease Reactivation and Reinfection with . Front Immunol. 2017 Jun 30;8:739. doi: 10.3389/fimmu.2017.00739. eCollection 2017. PMID: 28713372; PMCID: PMC5491555.
Copy Download .nbib Format: NLM
Analysis of the CDK4/6 Cell Cycle Pathway in Leiomyosarcomas as a Potential Target for Inhibition by Palbociclib.

Sarcoma

Böhm MJ, Marienfeld R, Jäger D, Mellert K, von Witzleben A, Brüderlein S, Wittau M, von Baer A, Schultheiss M, Mayer-Steinacker R, Rücker FG, Möller P, Bullinger L, Barth TFE.
PMID: 30804704
Sarcoma. 2019 Jan 21;2019:3914232. doi: 10.1155/2019/3914232. eCollection 2019.

Leiomyosarcoma (LMS) is characterized by high genomic complexity, and to date, no specific targeted therapy is available. In a genome-wide approach, we profiled genomic aberrations in a small cohort of eight primary tumours, two relapses, and eight metastases across...

Cite
Böhm MJ, Marienfeld R, Jäger D, et al. Analysis of the CDK4/6 Cell Cycle Pathway in Leiomyosarcomas as a Potential Target for Inhibition by Palbociclib. Sarcoma. 2019;2019:3914232doi: 10.1155/2019/3914232.
Böhm, M. J., Marienfeld, R., Jäger, D., Mellert, K., von Witzleben, A., Brüderlein, S., Wittau, M., von Baer, A., Schultheiss, M., Mayer-Steinacker, R., Rücker, F. G., Möller, P., Bullinger, L., & Barth, T. F. E. (2019). Analysis of the CDK4/6 Cell Cycle Pathway in Leiomyosarcomas as a Potential Target for Inhibition by Palbociclib. Sarcoma, 20193914232. https://doi.org/10.1155/2019/3914232
Böhm, Michael J, et al. "Analysis of the CDK4/6 Cell Cycle Pathway in Leiomyosarcomas as a Potential Target for Inhibition by Palbociclib." Sarcoma vol. 2019 (2019): 3914232. doi: https://doi.org/10.1155/2019/3914232
Böhm MJ, Marienfeld R, Jäger D, Mellert K, von Witzleben A, Brüderlein S, Wittau M, von Baer A, Schultheiss M, Mayer-Steinacker R, Rücker FG, Möller P, Bullinger L, Barth TFE. Analysis of the CDK4/6 Cell Cycle Pathway in Leiomyosarcomas as a Potential Target for Inhibition by Palbociclib. Sarcoma. 2019 Jan 21;2019:3914232. doi: 10.1155/2019/3914232. eCollection 2019. PMID: 30804704; PMCID: PMC6360577.
Copy Download .nbib Format: NLM
Drug-Drug Interaction of Ergotamine with a Combination of Darunavir, Abacavir, and Lamivudine Causing a Fatal Vasospastic Ischemia.

Case reports in emergency medicine

Petit E, Schoonheydt K, Meert P, Van Laer M.
PMID: 30662776
Case Rep Emerg Med. 2018 Dec 19;2018:4107450. doi: 10.1155/2018/4107450. eCollection 2018.

Ergotamine toxicity has become a rare condition which can be caused by, among others, drug-drug interaction. In this work we report a case with vasospastic ischemia induced by the wrongful combination of ergotamine with recently started Antiretroviral Therapy. Clinicians...

Cite
Petit E, Schoonheydt K, Meert P, et al. Drug-Drug Interaction of Ergotamine with a Combination of Darunavir, Abacavir, and Lamivudine Causing a Fatal Vasospastic Ischemia. Case Rep Emerg Med. 2018;2018:4107450doi: 10.1155/2018/4107450.
Petit, E., Schoonheydt, K., Meert, P., & Van Laer, M. (2018). Drug-Drug Interaction of Ergotamine with a Combination of Darunavir, Abacavir, and Lamivudine Causing a Fatal Vasospastic Ischemia. Case reports in emergency medicine, 20184107450. https://doi.org/10.1155/2018/4107450
Petit, Elisabeth, et al. "Drug-Drug Interaction of Ergotamine with a Combination of Darunavir, Abacavir, and Lamivudine Causing a Fatal Vasospastic Ischemia." Case reports in emergency medicine vol. 2018 (2018): 4107450. doi: https://doi.org/10.1155/2018/4107450
Petit E, Schoonheydt K, Meert P, Van Laer M. Drug-Drug Interaction of Ergotamine with a Combination of Darunavir, Abacavir, and Lamivudine Causing a Fatal Vasospastic Ischemia. Case Rep Emerg Med. 2018 Dec 19;2018:4107450. doi: 10.1155/2018/4107450. eCollection 2018. PMID: 30662776; PMCID: PMC6313968.
Copy Download .nbib Format: NLM
Ectopic expression of transcription factor BATF3 induces B-cell lymphomas in a murine B-cell transplantation model.

Oncotarget

Weiser C, Petkova MV, Rengstl B, Döring C, von Laer D, Hartmann S, Küppers R, Hansmann ML, Newrzela S.
PMID: 29662618
Oncotarget. 2018 Mar 23;9(22):15942-15951. doi: 10.18632/oncotarget.24639. eCollection 2018 Mar 23.

The mechanisms involved in malignant transformation of mature B and T lymphocytes are still poorly understood. In a previous study, we compared gene expression profiles of the tumor cells of Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL)...

Cite
Weiser C, Petkova MV, Rengstl B, et al. Ectopic expression of transcription factor BATF3 induces B-cell lymphomas in a murine B-cell transplantation model. Oncotarget. 2018;9(22):15942-15951doi: 10.18632/oncotarget.24639.
Weiser, C., Petkova, M. V., Rengstl, B., Döring, C., von Laer, D., Hartmann, S., Küppers, R., Hansmann, M. L., & Newrzela, S. (2018). Ectopic expression of transcription factor BATF3 induces B-cell lymphomas in a murine B-cell transplantation model. Oncotarget, 9(22), 15942-15951. https://doi.org/10.18632/oncotarget.24639
Weiser, Christian, et al. "Ectopic expression of transcription factor BATF3 induces B-cell lymphomas in a murine B-cell transplantation model." Oncotarget vol. 9,22 (2018): 15942-15951. doi: https://doi.org/10.18632/oncotarget.24639
Weiser C, Petkova MV, Rengstl B, Döring C, von Laer D, Hartmann S, Küppers R, Hansmann ML, Newrzela S. Ectopic expression of transcription factor BATF3 induces B-cell lymphomas in a murine B-cell transplantation model. Oncotarget. 2018 Mar 23;9(22):15942-15951. doi: 10.18632/oncotarget.24639. eCollection 2018 Mar 23. PMID: 29662618; PMCID: PMC5882309.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 84 entries